Anti-LAG3 Antibodies, Pharmaceutical Compositions, and Uses

Abstract

The present invention belongs to the field of biomedicine and relates to an anti-LAG3 antibody, a pharmaceutical composition containing the same, and use thereof. Specifically, the present invention relates to an anti-LAG3 antibody or an antigen-binding fragment thereof, the antibody comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising HCDR1 to HCDR3 having the amino acid sequences shown in SEQ ID NOs: 9 to 11, respectively, and the light chain variable region comprising LCDR1 to LCDR3 having the amino acid sequences shown in SEQ ID NOs: 12 to 14, respectively. The anti-LAG3 antibody of the present invention has excellent affinity and specificity, and is highly applicable.

Description

[Technical field]

[0001] The present invention is in the biomedical field and relates to anti-LAG3 antibodies, pharmaceutical compositions containing anti-LAG3 antibodies, and uses thereof. [Background technology]

[0002] Tumors, especially malignant tumors, are nowadays a serious health threat worldwide and the second leading cause of death among various diseases. In recent years, the incidence of these diseases has increased significantly. Malignant tumors are characterized by poor response to treatment, high rate of late metastasis, and poor prognosis. Although conventional treatment methods currently used clinically (e.g., radiation therapy, chemotherapy, and surgery) can significantly relieve pain and extend survival time, these methods have significant limitations and it is difficult to further improve their effectiveness.

[0003] Lymphocyte activation gene 3 (LAG3), or CD223, is a type I transmembrane protein of 498 amino acids and a member of the immunoglobulin superfamily (IgSF). LAG3 is primarily involved in the activation of activated CD4 + T cells and CD8 + LAG3 is expressed in T cells. It is also expressed in natural killer (NK) cells, B cells, regulatory T cells (Tregs), and plasmacytoid dendritic cells (pDCs) (Ruffo Elisa, Wu Richard C, Bruno Tullia C et al., Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. [J].Semin Immunol, 2019, 42: 101305.).

[0004] The LAG3 gene is located adjacent to the CD4 gene on human chromosome 12 (20p13.3), and both molecules have the same exons and introns. Although LAG3 and CD4 molecules are structurally similar, the amino acid sequence homology between them is only about 20%. Major histocompatibility complex class II (MHC II) molecules, liver sinusoidal endothelial cell lectin (LSECtin) molecules, and galectin-3 molecules are relevant ligands for LAG3. MHC class II molecules are the major ligand for LAG3. The affinity of LAG3 for MHC class II molecules (Kd: 60 nmol L -1 ) was 100-fold higher than that of the CD4 molecule, indicating that the LAG3 molecule could effectively compete with the CD4 molecule for binding to MHC class II molecules and inhibit T cell activation.

[0005] In the tumor microenvironment, expression of the immunosuppressive molecule LAG3 can be detected 24 hours after T cell activation, which in turn leads to T cell dysfunction or apoptosis. The LAG3 molecule dimerizes via its D1 domain (which has a proline-rich loop structure) and binds to CD4 + It specifically binds to MHC class II molecules in the "CD3-TCR-MHCII" first signaling axis of T cell activation. On the one hand, this blocks the signaling pathway for T cell activation, and on the other hand, the intracellular segment of the LAG3 molecule (KIEELE motif) generates an immunosuppressive signal, suppressing the activation of CD4 +Downregulates T cell activity. LAG3 molecule promotes the differentiation of Treg cells and is involved in downstream signaling of signal transducer and activator of transcription 5, thereby enhancing the inhibitory effect of Treg cells. This is one of the mechanisms by which tumors avoid killing by the immune system (Andrews Lawrence P, Marciscano Ariel E, Drake Charles G, et al., LAG3 (CD223) as a cancer immunotherapy target. [J]. Immunol Rev, 2017, 276: 80-96.).

[0006] Tumor-infiltrating CD8 in various malignant tumors + Several studies have shown that LAG3 is overexpressed in T cells. For example, in ovarian cancer, it is expressed by tumor-infiltrating CD8 T cells specific for the New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen. + T cells highly express PD-1 and LAG3 and have a reduced ability to produce IFN-γ and TNF-α, which results in lymphocyte inactivation. Galectin-3 and LSECtin mainly interact with LAG3 and upregulate CD8 + It regulates T cell activation and function. Also, melanoma antigen-specific T cells isolated from patients with metastatic melanoma show significant upregulation of the expression of LAG3 as well as other immune checkpoint molecules CTLA-4 and TIM-3 (Liu Hao, Li Xinying, Luo Longlong, et al., Research advances in biological function of lymphocyte activation gene-3 (LAG-3) molecule and clinical application of antibody drugs targeting LAG-3 [J]. Chinese Journal of Pharmacology and Toxicology, 2019, 33(01): 70-78.).

[0007] Currently, several LAG3 antibody drugs are in clinical research, of which Bristol Myers Squibb's leratolimab is the most advanced with 10 clinical studies ongoing. Most of these studies involve the combination of leratolimab and nivolumab for the treatment of tumors such as hematological malignancies, melanoma, glioblastoma, renal cell carcinoma, non-small cell lung cancer, and the like.

[0008] There is currently a need to develop new anti-LAG3 antibody drugs. Summary of the Invention

[0009] The present inventors have obtained an anti-LAG3 antibody through intensive research and creative efforts. The present inventors have surprisingly found that the anti-LAG3 antibody of the present invention (hereinafter sometimes abbreviated as the antibody or the antibody of the present invention) has excellent affinity and / or specificity, and is superior in one or more respects to a positive control antibody (e.g., leratolimab). The present invention is described in detail below.

[0010] One aspect of the present invention is an anti-LAG3 antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 to HCDR3 having the amino acid sequences set forth in SEQ ID NOs: 9 to 11, respectively, and the light chain variable region comprises LCDR1 to LCDR3 having the amino acid sequences set forth in SEQ ID NOs: 12 to 14, respectively; the heavy chain variable region comprises HCDR1 to HCDR3 having the amino acid sequences set forth in SEQ ID NOs: 9 to 11, respectively, and the light chain variable region comprises LCDR1 to LCDR3 having the amino acid sequences set forth in SEQ ID NOs: 12, 15, and 16, respectively; or The present invention relates to an anti-LAG3 antibody or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises HCDR1 to HCDR3 having the amino acid sequences set forth in SEQ ID NOs: 9 to 11, respectively, and the light chain variable region comprises LCDR1 to LCDR3 having the amino acid sequences set forth in SEQ ID NOs: 17, 15, and 14, respectively.

[0011] In some embodiments of the present invention, the heavy chain variable region of the antibody has the amino acid sequence set forth in SEQ ID NO:2 and the light chain variable region of the antibody has the amino acid sequence set forth in SEQ ID NO:4; the heavy chain variable region of the antibody has the amino acid sequence set forth in SEQ ID NO:2 and the light chain variable region of the antibody has the amino acid sequence set forth in SEQ ID NO:6; or the heavy chain variable region of the antibody has the amino acid sequence set forth in SEQ ID NO:2, and the light chain variable region of the antibody has the amino acid sequence set forth in SEQ ID NO:8; The antibody or antigen-binding fragment thereof is provided.

[0012] In some embodiments of the invention, the antibody or antigen-binding fragment thereof is provided, which is selected from a Fab, a Fab', a F(ab')2, a Fd, a Fv, a dAb, a complementarity determining region fragment, a single chain fragment variable, a humanized antibody, or a chimeric antibody.

[0013] In some embodiments of the invention, the antibody has an EC for human LAG3-mFc of less than 0.2 nM, e.g., less than 0.15 nM, less than 0.1 nM, less than 0.08 nM, less than 0.06 nM, or less than 0.05 nM, or less. 50 value, preferably the EC 50 The antibody or antigen-binding fragment thereof is provided, wherein the value is measured by indirect ELISA.

[0014] In some embodiments of the invention, there is provided an antibody or antigen-binding fragment thereof, wherein the antibody is derived from a species other than mouse, for example comprising non-CDR regions derived from a human antibody.

[0015] In some embodiments of the present invention, the antibody comprises a constant region derived from a human antibody; Preferably, the constant region of the antibody is selected from the constant region of human IgG1, IgG2, IgG3, or IgG4. The antibody or antigen-binding fragment thereof is provided.

[0016] In some embodiments of the present invention, an antibody or antigen-binding fragment thereof is provided, wherein the heavy chain constant region of the anti-LAG3 antibody is an Ig gamma-1 chain C region (e.g., as set forth in SEQ ID NO: 18) or an Ig gamma-4 chain C region (e.g., as set forth in SEQ ID NO: 20), and the light chain constant region of the anti-LAG3 antibody is an Ig kappa chain C region (e.g., as set forth in SEQ ID NO: 19).

[0017] In some embodiments of the invention, the anti-LAG3 antibody is a monoclonal antibody.

[0018] In some embodiments of the invention, the anti-LAG3 antibody is in the form of an immunoglobulin.

[0019] In some embodiments of the invention, the anti-LAG3 antibody is a single chain variable region fragment.

[0020] Another aspect of the invention relates to an antibody drug conjugate (ADC) comprising an antibody or antigen-binding fragment thereof, and a small molecule drug, wherein said antibody or antigen-binding fragment thereof is an anti-LAG3 antibody or antigen-binding fragment thereof of any of the embodiments of the invention; preferably, said small molecule drug is a small molecule cytotoxic drug; more preferably, said small molecule drug is an anti-tumor chemotherapeutic drug.

[0021] The chemotherapeutic agent may be a conventional antitumor chemotherapeutic agent, such as alkylating agents, antimetabolites, antitumor antibiotics, plant-based anticancer agents, hormones, and immunological agents.

[0022] In one or more embodiments of the invention, the antibody-drug conjugate is provided, wherein the antibody or antigen-binding fragment thereof is linked to a small molecule drug via a linker, which may be any linker known to those skilled in the art, such as a hydrazone bond, a disulfide bond, or a peptide bond.

[0023] In one or more embodiments of the present invention, the antibody-drug conjugate is provided, wherein the molar ratio of the antibody or antigen-binding fragment thereof to the small molecule drug is 1:(2 to 4), for example, 1:2, 1:3, or 1:4.

[0024] Yet another aspect of the invention pertains to an isolated nucleic acid molecule encoding an anti-LAG3 antibody of any of the embodiments of the invention.

[0025] Yet another aspect of the present invention pertains to a recombinant vector comprising the isolated nucleic acid molecule of the present invention.

[0026] Yet another aspect of the present invention relates to a host cell comprising the isolated nucleic acid molecule of the invention or the recombinant vector of the invention.

[0027] Yet another aspect of the invention relates to a method for preparing an antibody or antigen-binding fragment thereof of any of the embodiments of the invention, comprising culturing a host cell of the invention under suitable conditions and isolating said antibody or antigen-binding fragment thereof from the cell culture.

[0028] Yet another aspect of the present invention relates to a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of any of the embodiments of the present invention, or the antibody-drug conjugate of any of the embodiments of the present invention, wherein the pharmaceutical composition optionally further comprises a pharmacologically acceptable excipient.

[0029] Yet another aspect of the invention is the use of an antibody or antigen-binding fragment thereof of any of the embodiments of the invention, or an antibody-drug conjugate of any of the embodiments of the invention, in the preparation of a medicament for treating and / or preventing tumors or anemia, comprising: Preferably, the tumor is selected from one or more of ovarian cancer, esophageal cancer, melanoma, hematological malignancies, glioblastoma, renal cell carcinoma, lung cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, liver cancer, gastrointestinal cancer, breast cancer, brain cancer, pancreatic cancer, thyroid cancer, head and neck cancer, and kidney cancer; Preferably, the lung cancer is non-small cell lung cancer; Preferably, the hematological malignancy is leukemia; Preferably, the present invention relates to the use of an antibody or an antigen-binding fragment thereof, or an antibody-drug conjugate, wherein the esophageal cancer is esophageal squamous cell carcinoma.

[0030] The antibody or antigen-binding fragment thereof according to any of the embodiments of the present invention, or the antibody-drug conjugate according to any of the embodiments of the present invention, is for use in the treatment and / or prevention of tumor or anemia, comprising: Preferably, the tumor is selected from one or more of ovarian cancer, esophageal cancer, melanoma, hematological malignancies, glioblastoma, renal cell carcinoma, lung cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, liver cancer, gastrointestinal cancer, breast cancer, brain cancer, pancreatic cancer, thyroid cancer, head and neck cancer, and kidney cancer; Preferably, the lung cancer is non-small cell lung cancer; Preferably, the hematological malignancy is leukemia; Preferably, the esophageal cancer is esophageal squamous cell carcinoma.

[0031] Yet another aspect of the present invention is a method for treating and / or preventing tumors or anemia, comprising administering to a subject in need thereof an effective amount of the antibody or antigen-binding fragment thereof of any of the embodiments of the present invention, or the antibody-drug conjugate of any of the embodiments of the present invention; Preferably, the tumor is selected from one or more of ovarian cancer, esophageal cancer, melanoma, hematological malignancies, glioblastoma, renal cell carcinoma, lung cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, liver cancer, gastrointestinal cancer, breast cancer, brain cancer, pancreatic cancer, thyroid cancer, head and neck cancer, and kidney cancer; Preferably, the lung cancer is non-small cell lung cancer; Preferably, the hematological malignancy is leukemia; Preferably, the esophageal cancer is esophageal squamous cell carcinoma.

[0032] In the present invention, unless otherwise defined, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Also, the laboratory procedures of cell culture, molecular genetics, nucleic acid chemistry, and immunology used herein are routine procedures widely used in the corresponding fields. Meanwhile, in order to facilitate understanding of the present invention, the definitions and explanations of relevant terms are provided below.

[0033] As used herein, EC 50 The term refers to the concentration for 50% of the maximal effect, i.e., the concentration capable of producing 50% of the maximal effect.

[0034] The term "antibody" as used herein refers to an immunoglobulin molecule that generally consists of two pairs of polypeptide chains, each pair having one "light" (L) chain and one "heavy" (H) chain. Antibody light chains are classified as kappa and lambda light chains. Heavy chains are classified as mu, delta, gamma, alpha, or epsilon. Antibody isotypes are defined as IgM, IgD, IgG, IgA, and IgE. In the light and heavy chains, the variable and constant regions are connected by a "J" region of about 12 or more amino acids, and the heavy chains further include a "D" region of about 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of three domains, CH1, CH2, and CH3. Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region consists of one domain, CL. The constant regions of antibodies can mediate the binding of immunoglobulins to host tissues or factors, including the binding of various cells of the immune system (e.g., effector cells) to the first component (C1q) of the classical complement system. The VH and VL regions can be further divided into hypervariable regions (called complementarity determining regions (CDRs)), with conserved regions called framework regions (FRs) distributed between the hypervariable regions. Each VH and VL consists of three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of each heavy / light chain pair (VH and VL) form the antibody binding site.The assignment of amino acids to regions or domains is made according to Bethesda Md, Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, (1987 and 1991)) or Chothia & Lesk J. Mol. Biol., 1987; 196:901-917; Chothia et al., Nature, 1989; 342:878-883, or according to the definitions in the IMGT numbering system (see definitions in Ehrenmann F, Kaas Q, Lefranc M P., IMGT / 3Dstructure-DB and IMGT / DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF[J]., Nucleic acids research, 2009; 38(suppl_1):D301-D307).

[0035] The term "antibody" is not limited by any particular method for producing the antibody. For example, antibodies include recombinant antibodies, monoclonal antibodies, and polyclonal antibodies. The antibody may be of various isotypes, such as IgG (e.g., subtypes IgG1, IgG2, IgG3, or IgG4), IgA1, IgA2, IgD, IgE, or IgM.

[0036] The terms "mAb" and "monoclonal antibody" as used herein refer to an antibody or antibody fragment that is derived from a group of highly homologous antibodies, i.e., from a group of identical antibody molecules with the exception of natural mutations that may occur naturally. Monoclonal antibodies are highly specific to a single epitope on an antigen. Unlike monoclonal antibodies, polyclonal antibodies usually contain at least two or more different antibodies that generally recognize different epitopes on an antigen. Monoclonal antibodies can generally be obtained using hybridoma technology, first reported by Kohler et al. (Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity [J]. Nature, 1975; 256(5517): 495), but can also be obtained using recombinant DNA technology (see, e.g., U.S. Pat. No. 4,816,567).

[0037] The term "humanized antibody" as used herein refers to an antibody or antibody fragment obtained when the whole or part of the CDRs of a human immunoglobulin (receptor antibody) are replaced with the CDRs of a non-human antibody (donor antibody), which may be a non-human (e.g., mouse, rat, or rabbit) antibody with the expected specificity, affinity, or reactivity. Furthermore, some amino acid residues in the framework region (FR) of the receptor antibody can also be replaced with the corresponding amino acid residues of the non-human antibody or amino acid residues of other antibodies to further improve or optimize the performance of the antibody. For further details on humanized antibodies, see, e.g., Jones et al., Nature, 1986; 321:522-525; Reichmann et al., Nature, 1988; 332:323-329; Presta, Curr. Op. Struct. Biol., 1992; 2:593-596; and Clark, Immunol. Today, 2000; 21:397-402.

[0038] The term "isolated" as used herein refers to being obtained by artificial means from a natural state. When a particular "isolated" substance or component occurs in nature, it may be that the change occurs in its natural environment, or that it is isolated from the natural environment, or both. For example, if a particular non-isolated polynucleotide or polypeptide naturally occurs in a particular animal organism, and the same polynucleotide or polypeptide is isolated in high purity from such a natural state, it is called an isolated polynucleotide or polypeptide. The term "isolated" does not exclude the presence of artificial or synthetic substances or other impurities that do not affect the activity of the substance.

[0039] The term "vector" as used herein refers to a nucleic acid vehicle into which a polynucleotide can be inserted. If the vector allows for the expression of a protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction, or transfection so that the genetic material element carried by the vector can be expressed in the host cell. Vectors are well known to those skilled in the art, and examples include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs); phages, such as lambda phage or M13 phage; and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex viruses), poxviruses, baculoviruses, papilloma viruses, and papova viruses (such as SV40). The vector may contain various elements for regulating expression, examples of which include, but are not limited to, a promoter sequence, a transcription initiation sequence, an enhancer sequence, a selection element, and a reporter gene. Furthermore, the vector may contain a replication origin.

[0040] The term "host cell" as used herein refers to a cell into which a vector can be introduced, including, but not limited to, a prokaryotic cell, such as E. coli or Bacillus subtilis; a fungal cell, such as a yeast cell or Aspergillus; an insect cell, such as an S2 Drosophila cell or Sf9; or an animal cell, such as a fibroblast, a CHO cell, a GS cell, a COS cell, an NSO cell, a HeLa cell, a BHK cell, a HEK293 cell, or a human cell.

[0041] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and its target antigen. In some embodiments, an antibody that specifically binds to an antigen (or is specific for an antigen) is one in which the antibody binds to the antigen within about 10 -5 Less than m, e.g., about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 Affinity (K D ) means that the antibody binds to the antigen.

[0042] As used herein, "K D The term "dissociation equilibrium constant" refers to the dissociation equilibrium constant of a specific antibody-antigen interaction and is used to describe the binding affinity between an antibody and an antigen. A small dissociation equilibrium constant indicates strong antibody-antigen binding and high affinity between the antibody and the antigen. In general, antibodies have a dissociation equilibrium constant of about 10 -5 Less than m, e.g., about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 The dissociation equilibrium constant (K D ) to bind to antigens (such as the PD-1 protein). Dcan be determined using methods known to those of skill in the art, for example, using a Fortebio molecular interaction instrument.

[0043] As used herein, the terms "monoclonal antibody" and "mAb" have the same meaning and can be used interchangeably. The terms "polyclonal antibody" and "pAb" have the same meaning and can be used interchangeably. Also, herein, amino acids are generally represented using one-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.

[0044] The term "pharmacologically acceptable carriers and / or excipients" as used herein refers to carriers and / or excipients that are pharmacologically and / or physiologically compatible with the subject and active ingredient. Such carriers and / or excipients are well known in the art (see, for example, Remington's Pharmaceutical Sciences, edited by Gennaro AR, 19th Ed., Pennsylvania, Mack Publishing Company, 1995), and examples include, but are not limited to, pH adjusters, surfactants, adjuvants, and ionic strength enhancers. For example, a non-limiting example of a pH adjuster is phosphate buffer, a non-limiting example of a surfactant is a cationic, anionic, or nonionic surfactant, such as Tween-80, and a non-limiting example of an ionic strength enhancer is sodium chloride.

[0045] The term "effective amount" as used herein refers to an amount sufficient to obtain or at least partially obtain a desired effect. For example, a prophylactically effective amount for a disease (such as a tumor) refers to an amount sufficient to prevent, inhibit or delay the onset of the disease (such as a tumor), and a therapeutically effective amount refers to an amount sufficient to cure or at least partially inhibit the disease or its complications in a patient suffering from the disease. Determining such an effective amount is undoubtedly within the capabilities of a person skilled in the art. For example, an effective amount for therapeutic purposes depends on the severity of the disease to be treated; the overall state of the patient's own immune system; the general condition of the patient, such as age, weight and sex; the route of administration; and other treatments performed at the same time; etc.

[0046] In the present specification, the amino acid sequence of lymphocyte activation gene 3 (LAG3) includes the full-length LAG3 protein, or the LAG3 ECD, which is an extracellular fragment of LAG3, or a fragment containing the LAG3 ECD, and also includes a fusion protein of the full-length LAG3 protein or a fusion protein of the LAG3 ECD, such as a fragment fused with an Fc protein fragment (mFc or hFc) of mouse or human IgG. However, those skilled in the art will understand that mutations or alterations (including but not limited to substitutions, deletions, and / or additions) in the amino acid sequence of the LAG3 protein can occur naturally or can be artificially introduced without affecting its biological function. Thus, in the present invention, the term "LAG3 protein" includes all sequences including natural or artificial variants thereof. Furthermore, when a sequence fragment of the LAG3 protein is described, the corresponding sequence fragment in the natural or artificial variants thereof is also included. Effect of the Invention

[0047] Beneficial Effects of the Invention The present invention achieves one or more of the following advantages: (1) the anti-LAG3 antibody of the present invention has excellent affinity and specificity; and (2) The anti-LAG3 antibody of the present invention can effectively block the interaction between LAG3 and MHC-II and specifically alleviate the immunosuppression of LAG3 in an organism. [Brief description of the drawings]

[0048] [Figure 1] FIG. 1 shows the results of analyzing the binding activity of H7L8(hG1WT) to the antigen LAG3-mFc by indirect ELISA.

[0049] [Diagram 2] FIG. 2 shows the results of ELISA analysis of the binding activity of H7L8(hG4WT), H7L9(hG4WT), and H7L10(hG4WT) to the antigen human LAG3-mFc.

[0050] [Diagram 3] FIG. 3 shows the results of analyzing by FACS the binding activity of H7L8(hG4WT), H7L9(hG4WT), and H7L10(hG4WT) to the antigen LAG3 on the surface of 293T-LAG3 cells.

[0051] [Figure 4] FIG. 4 shows the results of a competition flow cytometry analysis of the activity of H7L8(hG4WT), H7L9(hG4WT), and H7L10(hG4WT) in competing with LAG3-mFc for binding to the antigen MHC II on the membrane surface of 293T-LAG3 cells.

[0052] [Diagram 5] FIG. 5 shows the biological activity of anti-LAG3 antibodies in promoting IFN-γ secretion analyzed by mixed lymphocyte reaction (MLR).

[0053] [Figure 6] FIG. 6 shows the biological activity of anti-LAG3 antibodies in promoting IL-2 secretion analyzed by mixed lymphocyte reaction (MLR).

[0054] [Figure 7] FIG. 7 shows the results of an analysis of the biological activity of anti-LAG antibodies in blocking the interaction between LAG-3 and MHC-II. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0055] Detailed Description The embodiments of the present invention will be described in detail below with reference to examples. Those skilled in the art will understand that the following examples are merely illustrative of the present invention and should not be interpreted as limiting the scope of the present invention. Examples in which no specific techniques or conditions are described are carried out according to techniques or conditions described in the literature of the field (see, for example, Molecular Cloning: A Laboratory Manual, authored by J. Sambrook et al., and translated by Huang Peitang et al., third edition, Science Press) or according to the accompanying instructions. If the manufacturer of the reagent or equipment used is not described, they are commercially available conventional products.

[0056] The positive control antibody, leratolimab, has the sequence set forth in US Patent Publication No. 20160326248(A1), with the heavy chain amino acid sequence set forth in SEQ ID NO: 1 and the light chain amino acid sequence set forth in SEQ ID NO: 2. leratolimab is an anti-LAG-3 antibody.

[0057] Leratolimab heavy chain amino acid sequence: QVQLQQWGAGLLKPSETLSLTCAVYGGSFSDYYWNWIRQPPGKGLEWIGEINHRGSTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYNWFDPWGQG TLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP PCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 23)

[0058] Leratolimab light chain amino acid sequence: EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 24)

[0059] The control antibody 14C12H1L1 (hG1TM) was an anti-PD-1 antibody constructed by Akeso Biopharma, lot number B105Y2080601.

[0060] Heavy chain amino acid sequence of 14C12H1L1 (hG1TM): EVQLVESGGGLVQPGGSLRLSCAASGFAFSSYDMSWVRQAPGKGLDWVATISGGGRYTYYPDSVKGRFTISRDNSKNNLYLQMNSLRAEDTALYYCANRYGEAWFAYWGQGTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP PCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 21)

[0061] Light chain amino acid sequence of 14C12H1L1 (hG1TM): DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 22)

[0062] The cell line 293T-LAG3 was constructed by Akeso Biopharma. The cell line 293T-LAG3 was prepared by viral infection of HEK293T cells using a third generation lentivirus system (see, e.g., A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini L., J Virol., 1998. 72(11): 8463-8471). The lentivirus expression vector used here was plenti6.3 / V5-huLAG3FL-BSD (LAG3, Genebank ID: NM_002277.4; vector plenti6.3 / V5-BSD, purchased from Invitrogen, catalog number K5315-20).

[0063] The cell line Raji-PDL1 was constructed by Akeso Biopharma. The cell line Raji-PDL1 was produced by viral infection of Raji cells using a third generation lentivirus system (see, e.g., A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini L., J Virol., 1998. 72(11): 8463-8471). The lentivirus expression vector used here was plenti6.3 / V5-PDL1 (PDL1, Genebank ID: NP_054862.1; vector plenti6.3 / V5, purchased from Invitrogen, catalog number K5315-20).

[0064] The cell line Jurkat-NFAT-PD1-LAG3 was constructed by Akeso Biopharma. The cell line Jurkat-NFAT-PD1-LAG3 was produced by viral infection of PD-1 effector cells (CPM, manufacturer: Promega, catalog number J112A) using a third generation lentivirus system (see, e.g., A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, and Naldini L., J Virol., 1998. 72(11): 8463-8471). The lentiviral expression vector used here was pCDH-huLAG3FL-RFP-NEO (LAG3, Genebank ID: NM_002277.4; vector pCDH-CMV-MCS-EF1-RFP+Neo, purchased from Youbio, catalog number VT9005). EXAMPLES

[0065] Preparation Example 1: Design and preparation of anti-LAG3 antibody 1. Antibody Design The inventors of the present application inventively designed a series of antibody sequences based on the known LAG3 protein sequence (NCBI reference sequence: NP_002277.4) and its three-dimensional crystal structure, etc. Through extensive screening and testing, humanized monoclonal antibodies that specifically bind to LAG3 were finally obtained and named H7L8, H7L9, and H7L10, respectively. The amino acid sequences of the heavy and light chain variable regions of the monoclonal antibodies and their coding sequences are as follows:

[0066] Nucleotide sequence of the heavy chain variable region H7v of H7L8 (360 bp): CAGGTGCAGCTGCAGCAGTGGGGAGCTGGACTGCTGAAACCTAGCGAGACACTGAGCCTGACCTGTGCTGTGTACGGCGGATCTATCAGCGATTACTACTGGAACTGGATCAGGCAGCCCCCTGGAAAGGGACTGGAATGGATCGGAGAGATCAACCACAGGGGCACCACCAACTCCAATCCC TCTCTGAAGAGCAGGGTGACACTGAGCCTCGACACAAGCAAGAATCAGTTCAGCCTGAAGCTGAGGTCCGTGACCGCTGCTGATACAGCTGTGTACTACTGTGCCTTCGGCTACAGCGATTACGAGTACGATTGGTTCGACCCTTGGGGCCAGGGAACACTGGTTACAGTGAGCTCC (SEQ ID NO: 1)

[0067] Amino acid sequence of the heavy chain variable region H7v of H7L8 (120 aa): QVQLQQWGAGLLKPSETLSLTCAVYGGSISDYYWNWIRQPPGKGLEWIGEINHRGTTNSNPSLKSRVTLSLDTSKNQFSLKLRSVTAADTAVYYCAFGYSDYEYDWFDPWGQGTLVTVSS (SEQ ID NO: 2)

[0068] Nucleotide sequence of the light chain variable region L8v of H7L8 (321 bp): GAGATCGTTCTGACCCAGAGCCCAGCTACACTGAGCCTGTCTCCTGGAGAGAGGGCTACACTGTCCTGCAGAGCTAGCCAGACCATCAGCAGCTACCTGGCTTGGTACCAGCAGAAGCCTGGCCAAGCTCCAAGGCTGCTGATCTACGACGCCTCTAATAGGGC CACCGGCATCCCTGCTAGATTCTCTGGAAGCGGCAGCGGAACCGACTTTACACTGACAATCAGCTCCCTGGAGCCCGAGGATTTCGCTGTTTACTACTGTCAGCAGCGCAGCAACTGGCCCATCACATTCGGACAGGGCACAAATCTGGAGATCAAG (SEQ ID NO: 3)

[0069] Amino acid sequence of the light chain variable region L8v of H7L8 (107 aa): EIVLTQSPATLSLSPGERATLSCRASQTISSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTNLEIK (SEQ ID NO: 4)

[0070] The nucleotide sequence of the heavy chain variable region H7v of H7L9 is identical to the nucleotide sequence of the heavy chain variable region H7v of H7L8 set forth in SEQ ID NO:1.

[0071] The amino acid sequence of the heavy chain variable region H7v of H7L9 is identical to the amino acid sequence of the heavy chain variable region H7v of H7L8 set forth in SEQ ID NO:2.

[0072] Nucleotide sequence of the light chain variable region L9v of H7L9 (321 bp): GAGATCGTTCTGACCCAGAGCCCAGCTACACTGAGCCTGTCTCCTGGAGAGAGGGCTACACTGTCCTGCAGAGCTAGCCAGACCATCAGCAGCTACCTGGCTTGGTACCAGCAGAAGCCTGGCCAAGCTCCAAGGCTGCTGATCTACGACGGCTCTAATAGGGC CACCGGCATCCCTGCTAGATTCTCTGGAAGCGGCAGCGGAACCGACTTTACACTGACAATCAGCTCCCTGGAGCCCGAGGATTTCGCTGTTTACTACTGTCAGCAGGCAGCAACTGGCCCCTCACATTCGGACAGGGCACAAATCTGGAGATCAAG (SEQ ID NO: 5)

[0073] Amino acid sequence of the light chain variable region L9v of H7L9 (107bp): EIVLTQSPATLSLSPGERATLSCRASQTISSYLAWYQQKPGQAPRLLIYDGSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTNLEIK (SEQ ID NO: 6)

[0074] The nucleotide sequence of the heavy chain variable region H7v of H7L10 is identical to the nucleotide sequence of the heavy chain variable region H7v of H7L8 set forth in SEQ ID NO:1.

[0075] The amino acid sequence of the heavy chain variable region H7v of H7L10 is identical to the amino acid sequence of the heavy chain variable region H7v of H7L8 set forth in SEQ ID NO:2.

[0076] Nucleotide sequence of the light chain variable region L10v of H7L10 (321 bp): GAGATCGTTCTGACCCAGAGCCCAGCTACACTGAGCCTGTCTCCTGGAGAGAGGGCTACACTGTCCTGCAGAGCTAGCCAGTCCATCAGCAGCTACCTGGCTTGGTACCAGCAGAAGCCTGGCCAAGCTCCAAGGCTGCTGATCTACGACGGCTCTAATAGGGC CACCGGCATCCCTGCTAGATTCTCTGGAAGCGGCAGCGGAACCGACTTTACACTGACAATCAGCTCCCTGGAGCCCGAGGATTTCGCTGTTTACTACTGTCAGCAGGCAGCAACTGGCCCATCACATTCGGACAGGGCACAAATCTGGAGATCAAG (SEQ ID NO: 7)

[0077] Amino acid sequence of the light chain variable region L10v of H7L10 (107bp): EIVLTQSPATLSLSPGERATLSCRASQSISSYLAWYQQKPGQAPRLLIYDGSNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTNLEIK (SEQ ID NO: 8)

[0078] The amino acid sequences of the CDRs of antibody H7L8 are as follows (according to the IMGT numbering system): HCDR1: GGSISDYY (SEQ ID NO: 9); HCDR2: INHRGTT (SEQ ID NO: 10); HCDR3: AFGYSDYEYDWFDP (SEQ ID NO: 11); LCDR1: QTISSY (SEQ ID NO: 12); LCDR2: DAS (SEQ ID NO: 13); and LCDR3: QQRSNWPIT (sequence number 14).

[0079] The amino acid sequences of the CDRs of antibody H7L9 are as follows (according to the IMGT numbering system): HCDR1: GGSISDYY (SEQ ID NO: 9); HCDR2: INHRGTT (SEQ ID NO: 10); HCDR3: AFGYSDYEYDWFDP (SEQ ID NO: 11); LCDR1: QTISSY (SEQ ID NO: 12); LCDR2: DGS (SEQ ID NO: 15); and LCDR3: QQRSNWPLT (sequence number 16).

[0080] The amino acid sequences of the CDRs of antibody H7L10 are as follows (according to the IMGT numbering system): HCDR1: GGSISDYY (SEQ ID NO: 9); HCDR2: INHRGTT (SEQ ID NO: 10); HCDR3: AFGYSDYEYDWFDP (SEQ ID NO: 11); LCDR1: QSISSY (SEQ ID NO: 17); LCDR2: DGS (SEQ ID NO: 15); and LCDR3: QQRSNWPIT (sequence number 14).

[0081] 2. Expression and purification of humanized antibody H7L8 (hG1WT) The heavy chain cDNA sequence (the coding sequence of the variable region is shown in SEQ ID NO:1; the constant region was the Ig gamma-1 chain C region) and the light chain cDNA sequence (the coding sequence of the variable region is shown in SEQ ID NO:3; the constant region was the human Ig kappa chain C region) of H7L8 (hG1WT) were separately cloned into pUC57simple vector (GenScript) to obtain plasmids pUC57simple-H7 and pUC57simple-L8, respectively. The plasmids pUC57simple-H7 and pUC57simple-L8 were digested (HindIII and EcoRI), respectively. The heavy and light chains were isolated by electrophoresis and separately subcloned into pcDNA3.1 vector, and the recombinant plasmids were extracted and co-transfected into 293F cells. After 7 days of cell culture, the medium was separated by high-speed centrifugation, and the supernatant was concentrated and loaded onto a HiTrap MabSelect SuRe column. The protein was eluted in one step using elution buffer. Target samples were isolated and buffer exchanged into PBS.

[0082] Amino acid sequence of the heavy chain constant region of H7L8 (hG1WT) ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 18)

[0083] Amino acid sequence of the light chain constant region of H7L8(hG1WT) RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 19)

[0084] 3. Expression and Purification of Humanized Antibodies H7L8(hG4WT), H7L9(hG4WT), and H7L10(hG4WT) The heavy chain cDNA sequences of H7L8 (hG4WT), H7L9 (hG4WT), and H7L10 (hG4WT) (the coding sequence of the variable region is shown in SEQ ID NO: 1; the constant region was an Ig gamma-4 chain C region), the light chain cDNA sequence of H7L8 (hG4WT) (the coding sequence of the variable region is shown in SEQ ID NO: 3; the constant region was a human Ig kappa chain C region), the light chain cDNA sequence of H7L9 (hG4WT) (the coding sequence of the variable region is shown in SEQ ID NO: 5; the constant region was an Ig kappa chain C region), The heavy and light chain cDNA sequences of H7L10 (hG4WT) (the coding sequence of the variable region is shown in SEQ ID NO: 7; the constant region was human Ig kappa chain C region) and H7L10 (hG4WT) light chain cDNA sequence (the coding sequence of the variable region is shown in SEQ ID NO: 7; the constant region was human Ig kappa chain C region) were separately cloned into pUC57simple vector (GenScript) to obtain plasmids pUC57simple-H7, pUC57simple-L8, pUC57simple-L9, and pUC57simple-L10, respectively. Plasmids pUC57simple-H7, pUC57simple-L8, pUC57simple-L9, and pUC57simple-L10 were each digested (HindIII and EcoRI). The heavy and light chains were isolated by electrophoresis and separately subcloned into pcDNA3.1 vector, and the recombinant plasmids were extracted and co-transfected into 293F cells. After 7 days of cell culture, the medium was separated by high-speed centrifugation, and the supernatant was concentrated and loaded onto a HiTrap MabSelect SuRe column. Proteins were eluted in one step with elution buffer. Target samples were isolated and the buffer was exchanged into PBS.

[0085] Amino acid sequence of the heavy chain constant region of H7L8 (hG4WT), H7L9 (hG4WT), or H7L10 (hG4WT) ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 20)

[0086] Amino acid sequence of the light chain constant region of H7L8(hG4WT), H7L9(hG4WT), or H7L10(hG4WT) RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 19)

[0087] Preparation Example 2: Preparation of human anti-egg lysozyme antibody The sequence of the human anti-hen egg lysozyme IgG (anti-HEL, or human IgG; abbreviated as hIgG) antibody was obtained from the variable region sequence of the Fab F10.6.6 sequence in the study reported by Acierno et al. entitled "Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies" (Acierno et al., J Mol Biol., 2007; 374(1): 130-46). The preparation method was as follows:

[0088] Nanjing Genscript Biology was commissioned to carry out amino acid codon optimization and gene synthesis of the heavy and light chain (full sequence or variable region) genes of human IgG antibody. By referring to the standard techniques introduced in "Guide to Molecular Cloning Experiments (Third Edition)" and by using standard molecular cloning techniques, such as PCR, enzyme digestion, DNA gel extraction, ligation transformation, colony PCR, or enzyme digestion identification, the heavy and light chain genes were subcloned into antibody heavy chain expression vectors and antibody light chain expression vectors of a mammalian expression system, respectively. The heavy and light chain genes of the recombinant expression vectors were further sequenced and analyzed. After confirming that the sequences were accurate, large or medium amounts of endotoxin-free expression plasmids were prepared. The heavy and light chain expression plasmids were transiently transfected into HEK293 cells to express the recombinant antibody. After 7 days of culture, the cell culture medium was collected and affinity purified using rProtein A column (GE). The quality of the obtained antibody samples was determined using standard analytical techniques of SDS-PAGE and SEC-HPLC.

[0089] Experimental Example 1: Analysis of the binding activity of anti-LAG3 antibody to antigen by ELISA ELISA plates were coated with 0.5 μg / mL human LAG3-mFc (constructed by Akeso Biopharma; Lot No. 20200417) and incubated overnight at 4°C. The antigen-coated ELISA plates were then washed once with PBST and blocked for 2 hours at 37°C using PBS solution containing 1% BSA as blocking solution. After blocking, the ELISA plates were washed three times with PBST. Antibodies serially diluted in PBST solution (antibody dilution gradient is shown in Table 1) were added. The ELISA plates containing the test antibodies were incubated for 30 minutes at 37°C and then washed three times with PBST. After washing, a working solution of HRP-labeled goat anti-human IgG FC(H+L) (Jackson, Cat. No. 109-035-098) secondary antibody diluted at a ratio of 1:5000 was added, and the plates were then incubated for 30 minutes at 37°C. After incubation, the plate was washed 4 times with PBST, and TMB (Neogen, 308177) was added in the dark for 5 minutes to develop the color, and then the stop solution was added to stop the color reaction. The ELISA plate was immediately placed in an ELISA plate reader, and the OD value of each well in the ELISA plate was read at 450 nm. Data were analyzed and processed using SoftMax Pro 6.2.1.

[0090] The analytical results are shown in Table 1 and Figure 1. [Table 1]

[0091] As can be seen from Figure 1, relatolimab and H7L8 (hG1WT) were able to effectively bind to the antigen human LAG3-mFc in a dose-dependent manner. The absorbance for each dose is shown in Table 1. Based on the quantitative analysis of the absorbance of the bound antibody, the binding efficiency EC of the antibodies relatolimab (positive control) and H7L8 (hG1WT) obtained by curve fitting calculation was 50 The values ​​were 0.106 nM and 0.045 nM, respectively.

[0092] The above experimental results show that under the same experimental conditions, H7L8(hG1WT) had effective binding activity to human LAG3-mFc, and the binding activity of H7L8(hG1WT) to human LAG3-mFc was stronger than the binding activity of the positive drug relatolimab to the same target.

[0093] Example 2: Analysis of the binding activity of anti-LAG3 antibodies to antigens by ELISA ELISA plates were coated with 2 μg / mL human LAG3-mFc and incubated overnight at 4°C. The antigen-coated ELISA plates were then washed once with PBST and blocked for 2 hours at 37°C using PBS solution containing 1% BSA as a blocking solution. After blocking, the ELISA plates were washed three times with PBST. Antibodies serially diluted in PBST solution (antibody dilution gradient is shown in Table 1) were added. The ELISA plates containing the test antibodies were incubated for 30 minutes at 37°C and then washed three times with PBST. After washing, a working solution of HRP-labeled goat anti-human IgG (H+L) (Jackson, Cat. No. 109-035-088) secondary antibody diluted at a ratio of 1:5000 was added, and the plates were then incubated for 30 minutes at 37°C. After incubation, the plate was washed 4 times with PBST, and TMB (Neogen, 308177) was added in the dark for 5 minutes to develop the color, and then the stop solution was added to stop the color reaction. The ELISA plate was immediately placed in an ELISA plate reader, and the OD value of each well in the ELISA plate was read at 450 nm. Data were analyzed and processed using SoftMax Pro 6.2.1.

[0094] The analysis results are shown in Table 2 and Figure 2. [Table 2]

[0095] The results show that antibodies H7L8(hG4WT), H7L9(hG4WT), and H7L10(hG4WT) could effectively bind to the antigen human LAG3-mFc in a dose-dependent manner, and they had binding activity comparable to that of the positive control antibody relatolimab.

[0096] Example 3: Analysis of the binding activity of anti-LAG3 antibodies to the antigen LAG3 on the cell surface by flow cytometry 1. Construction of 293T host cells expressing the antigen LAG3 The procedure was as follows:

[0097] Construction of 293T host cells expressing the antigen LAG3: According to the instructions of the Lipofectamine transfection kit (purchased from Invitrogen), the vector pLenti6.3 / V5-huLAG3FL-BSD containing LAG3 (vector pLenti6.3 was purchased from Invitrogen) was transfected into 293T cells, and a clone group 293T-LAG3 stably expressing LAG3 was obtained by screening.

[0098] 2. Binding of antibodies to antigens on the surface of 293T-LAG3 cells Antibody labeling and flow cytometer detection: The 293T-LAG3 host cells expressing the antigen LAG3 obtained in the previous step were digested with conventional pancreatin, and the number of cells in each collection tube was reduced to 3 × 10 5The LAG3 antibody dilutions were prepared in 1% PBSA (PBS containing 1% BSA) at final concentrations of 0.0123 nM, 0.123 nM, 1.23 nM, 3.7 nM, 11.1 nM, 33.3 nM, 100 nM, and 300 nM, respectively, and incubated with 293T cells expressing LAG3 on ice for 1 h. After centrifugation and several washes with 1% PBSA, 100 μL of FITC goat anti-human IgG (purchased from Jackson; catalog number 109-095-098) (diluted 1:500) was added to each tube, and the mixture was incubated on ice in the dark for 40 min. After one wash with 1% PBSA, 200 μL of 1% PBSA was added to resuspend the cells. The fluorescent signal was detected in the FITC channel on the flow cytometer.

[0099] The results of binding of the humanized anti-LAG3 antibody to 293T-LAG3 cells are shown in Figure 3. The binding efficiency of the anti-LAG3 antibody to the antigen on the surface of the 293T-LAG3 cells, EC 50 The values ​​are shown in Table 3. [Table 3]

[0100] As can be seen from Figure 3, the anti-LAG3 antibodies effectively bound to the target LAG3 protein on the surface of 293T-LAG3 host cells, and the binding activity of the anti-LAG3 antibodies H7L8 (hG4WT), H7L9 (hG4WT), and H7L10 (hG4WT) to the antigen on the surface of 293T-LAG3 cells was comparable to that of the positive control antibody relatolimab.

[0101] Example 4: Analysis of competitive binding activity of anti-LAG3 antibodies competing with LAG3-mFc for binding to antigen MHC II on the cell membrane surface by competitive flow cytometry Raji cells (medium: 1640+10% FBS) (Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences; Catalog No. TCHu 44) were added to EP tubes at 300,000 cells per sample. 1000 μL of 1% PBSA (PBS containing 1% BSA) was added. The mixture was centrifuged at 600×g for 5 min, and the supernatant was discarded. According to the experimental design, 100 μL of hIgG1 (constructed by Akeso Biopharma; Lot No. 20190410) with a final concentration of 300 nM was added to each tube, and the mixture was incubated on ice for 1 h. 200 μL of 1% PBSA was added to the incubated Raji cells, the mixture was centrifuged at 600×g for 5 min, and then the supernatant was removed. Meanwhile, according to the experimental design, the correspondingly diluted antibodies (at concentrations of 300nM, 100nM, 33.3nM, 11.1nM, 3.7nM, 1.23nM, 0.123nM, and 0.0123nM, respectively) were added to another new EP tube at 60μL / tube, and a blank group (PBSA+cells) was also designed. Then, 60μL of LAG3-mFc (constructed by Akeso Biopharma; Lot No. 20190508) (final concentration 3nM) was added to each corresponding antibody tube. The mixture was mixed well and pre-incubated on ice for 30 minutes. 100μL of the pre-incubated mixture of antibody and protein was added to the sample. The mixture was mixed well and incubated on ice in the dark for 1 hour. 200μL of 1% PBSA was added, and the mixture was centrifuged at 600×g for 5 minutes, after which the supernatant was removed, and then washed twice. 100 μL of APC anti-mouse antibody (Biolegend; Cat. No. 405308) (diluted 1:400) was added, the mixture was mixed well and incubated on ice in the dark for 40 minutes. 200 μL of 1% PBSA was added, the mixture was centrifuged at 600×g for 5 minutes, and the supernatant was removed. 200 μL of wash buffer was added to each tube to resuspend the cells, and then the suspension was transferred to a sample loading tube for testing on the flow cytometer.

[0102] The results are shown in Figure 4 and Table 4. Fluorometric analysis and curve fitting revealed the competitive binding EC 50 The values ​​were calculated to be 1.153 nM, 1.342 nM, 1.317 nM, and 1.267 nM, respectively. [Table 4]

[0103] The results show that antibodies H7L8(hG4WT), H7L9(hG4WT), and H7L10(hG4WT) were able to effectively block the binding of LAG-3 to MHC II on the surface of Raji host cells in a dose-dependent manner and had activity comparable to the positive control antibody relatolimab.

[0104] Experimental Example 5: Analysis of the biological activity of anti-LAG3 antibody in promoting IFN-γ and IL-2 secretion by mixed lymphocyte reaction (MLR) 1.Analysis of the biological activity of anti-LAG3 antibody in promoting IFN-γ secretion in the Raji-PDL1 mixed lymphocyte reaction system Raji-PDL1 cells were subcultured as usual. PBMCs were thawed and cultured in 10 mL 1640 complete medium and stimulated with 0.5 μg / mL SEB (Staphylococcal Enterotoxin B) (Dianotech; Cat. No. S010201) for 2 days. The Raji-PDL1 cells were treated with 25 μg / mL MMC (Stressmarq; Cat. No. SIH-246-10MG) and incubated for 1 h at 37° C. in a 5% CO2 incubator. PBMCs stimulated with SEB for 2 days and Raji-PDL1 cells treated with MMC for 1 h were harvested, washed twice with PBS, resuspended in complete medium (i.e., RPMI1640 + 10% FBS) and counted. The PBMCs and Raji-PDL1 cells were plated in U-shaped 96-well plates (Corning; Model No. 3799) at 10×10 4Cells / well were added, respectively, and co-cultured. Based on the experimental design, antibodies (final concentrations of each antibody when used alone or in combination were 300nM, 30nM, and 3nM) were added and cells were co-cultured for 3 days in an incubator. After 3 days, cells were centrifuged at 1200 rpm for 5 minutes, and cell culture supernatants were collected and IFN-γ was analyzed by ELISA.

[0105] As shown in Figure 5, co-culture of human PBMCs and Raji-PDL1 cells promoted IFN-γ secretion in PBMCs, and the addition of antibodies to the co-culture system significantly induced further IFN-γ secretion in PBMCs. Regarding the degree of activity to promote IFN-γ secretion, the anti-LAG3 antibodies H7L8 (hG4WT), H7L9 (hG4WT), and H7L10 (hG4WT) each combined with 14C12H1L1 (hG1TM), and the positive control antibody leratolimab combined with 14C12H1L1 (hG1TM) promoted IFN-γ secretion with the same degree of activity.

[0106] 2. Analysis of the biological activity of anti-LAG antibody in promoting IL-2 secretion in the Raji-PDL1 mixed lymphocyte reaction system Raji-PDL1 cells were subcultured as usual. PBMCs were thawed and cultured in 10 mL of 1640 complete medium and stimulated with 0.5 μg / mL SEB (Staphylococcal Enterotoxin B; purchased from Dianotech; Cat. No. S010201) for 2 days. The Raji-PDL1 cells were treated with 25 μg / mL MMC (Stressmarq; Cat. No. SIH-246-10MG) and incubated for 1 h at 37° C. in a 5% CO2 incubator. PBMCs stimulated with SEB for 2 days and Raji-PDL1 cells treated with MMC for 1 h were harvested, washed twice with PBS, resuspended in complete medium (i.e., RPMI1640 + 10% FBS) and counted. The PBMCs and Raji-PDL1 cells were plated in U-shaped 96-well plates (Corning; Model No. 3799) at 10×10 4Cells / well were added, respectively, and co-cultured. Based on the experimental design, antibodies (final concentrations of each antibody when used alone or in combination were 300 nM, 30 nM, and 3 nM) were added and cells were co-cultured for 3 days. After 3 days, cells were centrifuged at 1200 rpm for 5 min, cell culture supernatants were collected, and IL-2 was analyzed by ELISA.

[0107] As shown in Figure 6, co-culture of human PBMC (derived from a healthy donor) with Raji-PDL1 cells promoted IL-2 secretion in PBMC to some extent. In addition, the addition of antibodies to the co-culture system significantly induced further IL-2 secretion in PBMC, which showed a dose-dependent relationship. Regarding the degree of activity to promote IL-2 secretion, the anti-LAG3 antibodies H7L8 (hG4WT), H7L9 (hG4WT), and H7L10 (hG4WT) were combined with 14C12H1L1 (hG1TM), and the positive control antibody relatolimab was combined with 14C12H1L1 (hG1TM), and promoted IL-2 secretion with the same degree of activity.

[0108] Experimental Example 6: Analysis of the biological activity of anti-LAG antibodies in blocking the interaction between LAG-3 and MHC-II (reporter gene method) Jurkat-NFAT-PD1-LAG3 cells and Raji cells were used as a reporter gene system. After adding the superantigen SEE, the TCR-NFAT signaling pathway was activated and luciferase expression was induced. LAG-3 on Jurkat cells was bound to MHC-II on Raji cells such that the NFAT signaling pathway was inhibited and luciferase expression was downregulated. The antibody relieved the inhibition of luciferase expression by specifically binding to LAG-3, resulting in upregulation.

[0109] Jurkat-NFAT-PD1-LAG3 and Raji cells (purchased from Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences; Catalog No. TCHu 44) were harvested and centrifuged at 110 × g for 5 min, and the supernatant was then removed. The cells were then resuspended in 1640 + 10% FBS medium and counted. Jurkat-NFAT-PD1-LAG3 cells were plated at 10 5 Raji cells were seeded at 10 μL / well. According to the experimental design, antibodies (final concentrations of 0.3 nM, 3 nM, and 300 nM, respectively) were added at 10 μL / well, and the mixture was preincubated at 37°C in a 5% CO2 incubator for 30 min. Meanwhile, SEE (Staphylococcal Enterotoxin E; purchased from Toxin Technology; Cat. No. ET404) (final concentration 0.05 ng / mL) was added to the Raji cells, and the mixture was incubated at 37°C in a 5% CO2 incubator for 30 min. After 30 min, the SEE-treated Raji cells were transferred to the 96-well plate containing the Jurkat-NFAT-PD1-LAG3 cells at 2 × 10 4 Cells / well (40 μL / well) were added to a final volume of 80 μL in each well. The mixture was mixed well and incubated at 37°C in a 5% CO2 incubator for 6 hours. After incubation, the culture plate was removed and brought to room temperature. Bright-Glo™ Luciferase Assay System (purchased from Promega; Catalog No. E2650) was added at 80 μL / well and the mixture was incubated in the dark for 2 minutes. The RLU value was then read. The isotype control hIgG1DM was constructed by Akeso Biopharma with lot number 20181107. The isotype control hG4WT was constructed by Akeso Biopharma with lot number 20190910.

[0110] As shown in Figure 7, anti-LAG antibodies H7L8 (hG4WT), H7L9 (hG4WT), and H7L10 (hG4WT), as well as the positive control antibody relatolimab, could block the interaction between LAG-3 and MHC-II and upregulate luciferase expression. And the activities of anti-LAG antibodies H7L8 (hG4WT), H7L9 (hG4WT), and H7L10 (hG4WT) were all superior to the control antibody relatolimab.

[0111] Although the specific embodiments of the present invention have been described in detail, those skilled in the art will understand that, according to any teaching disclosed herein, various modifications and substitutions can be made to those details, and all of these modifications are included within the protection scope of the present invention. The full scope of the present invention is provided by the appended claims and any equivalents thereof.

Claims

1. An anti-LAG3 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1 to HCDR3 having the amino acid sequences set forth in SEQ ID NOS: 9 to 11, respectively, and the light chain variable region comprises LCDR1 to LCDR3 having the amino acid sequences set forth in SEQ ID NOS: 12 to 14, respectively; the heavy chain variable region comprises HCDR1 to HCDR3 having the amino acid sequences set forth in SEQ ID NOs:9 to 11, respectively, and the light chain variable region comprises LCDR1 to LCDR3 having the amino acid sequences set forth in SEQ ID NOs:12, 15, and 16, respectively; or An anti-LAG3 antibody or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises HCDR1 to HCDR3 having the amino acid sequences set forth in SEQ ID NOs:9 to 11, respectively, and the light chain variable region comprises LCDR1 to LCDR3 having the amino acid sequences set forth in SEQ ID NOs:17, 15, and 14, respectively.

2. The antibody or antigen-binding fragment thereof according to claim 1, the heavy chain variable region of the antibody has the amino acid sequence set forth in SEQ ID NO:2 and the light chain variable region of the antibody has the amino acid sequence set forth in SEQ ID NO:4; the heavy chain variable region of the antibody has the amino acid sequence set forth in SEQ ID NO:2 and the light chain variable region of the antibody has the amino acid sequence set forth in SEQ ID NO:6; or An antibody or an antigen-binding fragment thereof, wherein the heavy chain variable region of the antibody has the amino acid sequence set forth in SEQ ID NO: 2 and the light chain variable region of the antibody has the amino acid sequence set forth in SEQ ID NO:

8.

3. The antibody or antigen-binding fragment thereof is Fab, Fab', F(ab') ２ 2. The antibody or antigen-binding fragment thereof of claim 1, which is selected from an Fd, Fv, dAb, complementarity determining region fragment, single chain variable region fragment, humanized antibody, or chimeric antibody.

4. The antibody has an EC50 binding affinity to human LAG3-mFc of less than 0.2 nM, e.g., less than 0.15 nM, less than 0.1 nM, less than 0.08 nM, less than 0.06 nM, or less than 0.05 nM, or less. ５０ value, preferably the EC ５０ The antibody or antigen-binding fragment thereof of claim 1 , wherein the value is measured by indirect ELISA.

5. 2. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody comprises non-CDR regions derived from a species other than mouse, for example, a human antibody.

6. the antibody comprises a constant region derived from a human antibody; Preferably, the constant region of the antibody is selected from the constant region of human IgG1, IgG2, IgG3, or IgG4. The antibody or antigen-binding fragment thereof according to claim 1.

7. The antibody or antigen-binding fragment thereof according to claim 1, wherein the heavy chain constant region of the anti-LAG3 antibody is an Ig gamma-1 chain C region (e.g., as set forth in SEQ ID NO: 18) or an Ig gamma-4 chain C region (e.g., as set forth in SEQ ID NO: 20), and the light chain constant region of the anti-LAG3 antibody is an Ig kappa chain C region (e.g., as set forth in SEQ ID NO: 19).

8. An antibody-drug conjugate comprising an antibody or an antigen-binding fragment thereof, and a small molecule drug, wherein the antibody or antigen-binding fragment thereof is the antibody or antigen-binding fragment thereof according to any one of claims 1 to 7; preferably, the small molecule drug is a small molecule cytotoxic drug; more preferably, the small molecule drug is an anti-tumor chemotherapeutic drug.

9. The antibody-drug conjugate of claim 8, wherein the antibody or antigen-binding fragment thereof is linked to the small molecule drug via a linker, for example, the linker is a hydrazone bond, a disulfide bond, or a peptide bond.

10. 9. The antibody-drug conjugate of claim 8, wherein the molar ratio of the antibody or antigen-binding fragment thereof to the small molecule drug is 1:(2-4).

11. An isolated nucleic acid molecule encoding the anti-LAG3 antibody of any one of claims 1 to 7.

12. A recombinant vector comprising the isolated nucleic acid molecule of claim 11.

13. 12. A host cell comprising the isolated nucleic acid molecule or recombinant vector of claim 11, wherein the recombinant vector comprises the isolated nucleic acid molecule of claim 11.

14. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, wherein the pharmaceutical composition optionally further comprises a pharmacologically acceptable excipient.

15. A pharmaceutical composition comprising the antibody-drug conjugate of claim 8, wherein the pharmaceutical composition optionally further comprises a pharmacologically acceptable accessory ingredient.

16. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 7 in the preparation of a medicament for treating and / or preventing tumors or anemia, comprising: Preferably, the tumor is selected from one or more of ovarian cancer, esophageal cancer, melanoma, hematological malignancies, glioblastoma, renal cell carcinoma, lung cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, liver cancer, gastrointestinal cancer, breast cancer, brain cancer, pancreatic cancer, thyroid cancer, head and neck cancer, and kidney cancer; Preferably, the lung cancer is non-small cell lung cancer; Preferably, the hematological malignancy is leukemia; Preferably, the esophageal cancer is esophageal squamous cell carcinoma.

17. Use of the antibody-drug conjugate of claim 8 in the preparation of a medicament for treating and / or preventing tumors or anemia, comprising: Preferably, the tumor is selected from one or more of ovarian cancer, esophageal cancer, melanoma, hematological malignancies, glioblastoma, renal cell carcinoma, lung cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, liver cancer, gastrointestinal cancer, breast cancer, brain cancer, pancreatic cancer, thyroid cancer, head and neck cancer, and kidney cancer; Preferably, the lung cancer is non-small cell lung cancer; Preferably, the hematological malignancy is leukemia; Preferably, the esophageal cancer is esophageal squamous cell carcinoma.

18. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 7 for use in the treatment and / or prevention of tumors or anemia, Preferably, the tumor is selected from one or more of ovarian cancer, esophageal cancer, melanoma, hematological malignancies, glioblastoma, renal cell carcinoma, lung cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, liver cancer, gastrointestinal cancer, breast cancer, brain cancer, pancreatic cancer, thyroid cancer, head and neck cancer, and kidney cancer; Preferably, the lung cancer is non-small cell lung cancer; Preferably, the hematological malignancy is leukemia; Preferably, the esophageal cancer is esophageal squamous cell carcinoma.

19. The antibody-drug conjugate of claim 8 for use in the treatment and / or prevention of tumors or anemia, Preferably, the tumor is selected from one or more of ovarian cancer, esophageal cancer, melanoma, hematological malignancies, glioblastoma, renal cell carcinoma, lung cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, liver cancer, gastrointestinal cancer, breast cancer, brain cancer, pancreatic cancer, thyroid cancer, head and neck cancer, and kidney cancer; Preferably, the lung cancer is non-small cell lung cancer; Preferably, the hematological malignancy is leukemia; Preferably, the esophageal cancer is esophageal squamous cell carcinoma.

20. A pharmaceutical composition for treating and / or preventing tumors or anemia, the pharmaceutical composition comprising an effective amount of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 7; Preferably, the tumor is selected from one or more of ovarian cancer, esophageal cancer, melanoma, hematological malignancies, glioblastoma, renal cell carcinoma, lung cancer, prostate cancer, bladder cancer, colon cancer, rectal cancer, liver cancer, gastrointestinal cancer, breast cancer, brain cancer, pancreatic cancer, thyroid cancer, head and neck cancer, and kidney cancer; Preferably, the lung cancer is non-small cell lung cancer; Preferably, the hematological malignancy is leukemia; Preferably, the pharmaceutical composition, wherein the esophageal cancer is esophageal squamous cell carcinoma.

Images